Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NOVAVAX INCNVAX · Entity 4632 | EVP, R&D | April 14, 2026 | April 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NOVAVAX INC
Report date April 14, 2026 · Filed April 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.46 · Expires 2036-04-14 | Direct | 99,500 |
Reported balance
After 2026-04-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-14 · Grant · Acquired 99,500 · Balance 99,500 F1: Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,600 |
Reported balance
After 2026-04-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-14 · Grant · Acquired 66,000 · Balance 6,600 F2: Each RSU represents a contingent right to receive one share of the "Company" common stock. F3: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the April 14, 2026 grant date, in each case subject to continued employment with the Company through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.
F2: Each RSU represents a contingent right to receive one share of the "Company" common stock.
F3: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the April 14, 2026 grant date, in each case subject to continued employment with the Company through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 14, 2026 Filed Apr 16, 2026 22:13 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 66,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-044486 · tm2611965-2_4seq1.xml · derivative · entry 2 Walker Robert Edward · CIK 0002127840 · EVP, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,600 Underlying: Common Stock · 66,000 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the "Company" common stock. F3 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the April 14, 2026 grant date, in each case subject to continued employment with the Company through such vesting date. F3 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the April 14, 2026 grant date, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 22:13 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 99,500 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001104659-26-044486 · tm2611965-2_4seq1.xml · derivative · entry 1 Walker Robert Edward · CIK 0002127840 · EVP, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,500 Underlying: Common Stock · 99,500 shares Expires 2036-04-14 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.